WO2003052069A2 - Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation - Google Patents

Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation Download PDF

Info

Publication number
WO2003052069A2
WO2003052069A2 PCT/US2002/039867 US0239867W WO03052069A2 WO 2003052069 A2 WO2003052069 A2 WO 2003052069A2 US 0239867 W US0239867 W US 0239867W WO 03052069 A2 WO03052069 A2 WO 03052069A2
Authority
WO
WIPO (PCT)
Prior art keywords
fljl
apaf
agent
assay
pathway
Prior art date
Application number
PCT/US2002/039867
Other languages
English (en)
Other versions
WO2003052069A3 (fr
Inventor
Tak Hung
Michael Costa
Monique Nicoll
Roel P. Funke
Danxi Li
Original Assignee
Exelixis, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc filed Critical Exelixis, Inc
Priority to AU2002360586A priority Critical patent/AU2002360586A1/en
Publication of WO2003052069A2 publication Critical patent/WO2003052069A2/fr
Publication of WO2003052069A3 publication Critical patent/WO2003052069A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the apoptosis activator Apaf-1 shows low levels of expression in many melanoma cell lines and a high rate of allelic loss in metastatic melanomas (Soengas et al, 2000, Nature 409: 207).
  • Apaf-1 -negative melanomas are often chemoresistant and defective in Apaf-1 -mediated apoptosis.
  • restoring Apaf-1 expression induces chemosensitivity and apoptosis .
  • model organisms such as C. elegans
  • C. elegans The ability to manipulate the genomes of model organisms such as C. elegans provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and - their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Dulubova I, et al, J Neurochem 2001 Apr;77(l):229-38; Cai T, et al., Diabetologia 2001 Jan;44(l):81-8; Pasquinelli AE, et al., Nature.
  • a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the genetic entry point.
  • FLJl 115 genes that modify the Apaf-1 pathway in C. elegans', and identified their human orthologs, hereinafter referred to as FLJl 115.
  • the invention provides methods for utilizing these Apaf-1 modifier genes and polypeptides to identify FLJ1115-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired Apaf-1 function and/or FLJl 115 function.
  • Preferred FLJl 115-modulating agents specifically bind to FLJl 115 polypeptides and restore Apaf-1 function.
  • FLJl 115-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress FLJl 115 gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).
  • nucleic acid modulators such as antisense oligomers and RNAi that repress FLJl 115 gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).
  • FLJl 115 modulating agents may be evaluated by any convenient in vitro or in vivo assay for molecular interaction with an FLJl 115 polypeptide or nucleic acid.
  • candidate FLJl 115 modulating agents are tested with an assay system comprising a FLJl 115 polypeptide or nucleic acid.
  • Agents that produce a change in the activity of the assay system relative to controls are identified as candidate Apaf-1 modulating agents.
  • the assay system may be cell-based or cell-free.
  • FLJl 115- modulating agents include FLJl 115 related proteins (e.g.
  • a small molecule modulator is identified using a binding assay.
  • the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.
  • candidate Apaf-1 pathway modulating agents are further tested using a second assay system that detects changes in the Apaf-1 pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent.
  • the second assay system may use cultured cells or non-human animals.
  • the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the Apaf-1 pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).
  • the invention further provides methods for modulating the FLJl 115 function and/or the Apaf-1 pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a FLJl 115 polypeptide or nucleic acid.
  • the agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated the Apaf-1 pathway.
  • RNA inhibition Methods for using RNAi to silence genes in C. elegans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); WO9932619). Genes causing altered phenotypes in the worms were identified as modifiers of the Apaf-1 pathway. A modifier of particular interest, W02D3.4, was identified.
  • vertebrate orthologs of these modifiers and preferably the human orthologs, FLJl 115 genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective Apaf-1 signaling pathway, such as cancer.
  • FLJl 115 function In vitro and in vivo methods of assessing FLJl 115 function are provided herein. Modulation of the FLJl 115 or their respective binding partners is useful for understanding the association of the Apaf-1 pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for Apaf-1 related pathologies. FLJl 115-modulating agents that act by inhibiting or enhancing FLJl 115 expression, directly or indirectly, for example, by affecting an FLJl 115 function such as binding activity, can be identified using methods provided herein. FLJl 115 modulating agents are useful in diagnosis, therapy and pharmaceutical development.
  • Genbank referenced by Genbank identifier (GI) number
  • GI# 8922902 SEQ ID NO:l
  • GI# 8922903 SEQ ID NO:2
  • FLJl 115 polypeptide refers to a full-length FLJl 115 protein or a functionally active fragment or derivative thereof.
  • a "functionally active" FLJl 115 fragment or derivative exhibits one or more functional activities associated with a full- length, wild- type FLJl 115 protein, such as antigenic or i munogenic activity, ability to bind natural cellular substrates, etc.
  • the functional activity of FLJl 115 proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan et al., eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below.
  • a functionally active FLJl 115 polypeptide is a FLJl 115 derivative capable of rescuing defective endogenous FLJl 115 activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species.
  • functionally active fragments also include those fragments that comprise one or more structural domains of an FLJl 115, such as a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260- 2).
  • the DUF6 domain of FLJl 115 from GI# 8922903 is located at approximately amino acid residues 219-338 (PFAM 00892).
  • Methods for obtaining FLJl 115 polypeptides are also further described below.
  • preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of SEQ ID NO:2 (an FLJl 115).
  • the fragment comprises the entire functionally active domain.
  • FLJl 115 nucleic acid refers to a DNA or RNA molecule that encodes a FLJl 115 polypeptide.
  • the FLJl 115 polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human FLJl 115.
  • Methods of identifying orthlogs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3- dimensional structures.
  • Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from, the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA et al, Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and or residues of orthologous proteins and to generate phylogenetic trees.
  • CLUSTAL Thinson JD et al, 1994, Nucleic Acids Res 22:4673-4680
  • orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species.
  • Structural threading or other analysis of protein folding e.g., using software by ProCeryon, Biosciences, Salzburg, Austria
  • protein folding may also identify potential orthologs.
  • a gene duplication event follows speciation, a single gene in one species, such as C. elegans, may correspond to multiple genes (paralogs) in another, such as human.
  • the term "orthologs" encompasses paralogs.
  • percent (%) sequence identity with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0al9 (Altschul et al, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values.
  • the HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched.
  • a % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.
  • Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleuci ⁇ e, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.
  • an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, Advances in Applied Mathematics 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, J. of Molec.Biol., 147:195-197; Nicholas et al, 1998, "A tutorial on Searching Sequence Databases and Sequence Scoring Methods” (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, Genomics 11:635-650).
  • This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl.
  • Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of SEQ ID NO:l.
  • the stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (e.g., Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)).
  • a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of SEQ ID NO:l under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (IX SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardf s solution, 0.05% sodium pyrophosphate and 100 ⁇ g/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, IX Denhardt's solution, 100 ⁇ g/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for lh in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).
  • SSC single strength citrate
  • moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl ( ⁇ H7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1 % SDS .
  • low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.
  • FLJl 115 nucleic acids and polypeptides useful for identifying and testing agents that modulate FLJl 115 function and for other applications related to the involvement of FLJl 115 in the Apaf-1 pathway.
  • FLJl 115 nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes.
  • Fusion proteins may require the addition of specific tags (e.g., generation of fusion proteins).
  • Overexpression of an FLJl 115 protein for assays used to assess FLJl 115 function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities.
  • recombinant FLJl 115 is expressed in a cell line known to have defective Apaf-1 function.
  • the recombinant cells are used in cell-based screening assay systems of the invention, as described further below.
  • the nucleotide sequence encoding an FLJl 115 polypeptide can be inserted into any appropriate expression vector.
  • the necessary transcriptional and translational signals can derive from the native FLJl 115 gene and/or its flanking regions or can be heterologous.
  • a variety of host- vector expression systems may be utilized, such as mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA.
  • an isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.
  • the expression vector can comprise a promoter operably linked to an FLJl 115 gene nucleic acid, one or more origins of replication, and, one or more selectable markers (e.g. thymidine kinase activity, resistance to antibiotics, etc.).
  • selectable markers e.g. thymidine kinase activity, resistance to antibiotics, etc.
  • recombinant expression vectors can be identified by assaying for the expression of the FLJl 115 gene product based on the physical or functional properties of the FLJl 115 protein in in vitro assay systems (e.g. immunoassays).
  • the FLJl 115 protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection.
  • a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product.
  • a chimeric product may also be made by protein synthetic techniques, e.g. by use of a peptide synthesizer (Hunkapiller et al, Nature (1984) 310:105-111).
  • the gene product can be isolated and purified using standard methods (e.g. ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis).
  • native FLJl 115 proteins can be purified from natural sources, by standard methods (e.g. immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.
  • the methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of FLJl 115 or other genes associated with the Apaf-1 pathway.
  • mis-expression encompasses ectopic expression, over- expression, under-expression, and non-expression (e.g. by gene knock-out or blocking expression that would otherwise normally occur).
  • Animal models that have been genetically modified to alter FLJl 115 expression may be used in in vivo assays to test for activity of a candidate Apaf-1 modulating agent, or to further assess the role of FLJl 115 in a Apaf-1 pathway process such as apoptosis or cell proliferation.
  • the altered FLJl 115 expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal FLJl 115 expression.
  • the genetically modified animal may additionally have altered Apaf-1 expression (e.g. Apaf-1 knockout).
  • Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others.
  • Preferred non-mammalian species include zebrafish, C. elegans, and Drosophila.
  • Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells).
  • Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.
  • transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat.
  • the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous FLJl 115 gene that results in a decrease of FLJl 115 function, preferably such that FLJl 115 expression is undetectable or insignificant.
  • Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out.
  • the transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species.
  • a mouse FLJl 115 gene is used to construct a homologous recombination vector suitable for altering an endogenous FLJl 115 gene in the mouse genome.
  • homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner etal, Nature (1989) 338:153-156).
  • knock-out animals such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH et al., (1994) Scan J Immunol 40:257-264; Declerck PJ et al., (1995) J Biol Chem. 270:8397-400).
  • the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the FLJl 115 gene, e.g., by introduction of additional copies of FLJl 115, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the FLJl 115 gene.
  • a regulatory sequence include inducible, tissue-specific, and constitutive promoters and enhancer elements.
  • the knock-in can be homozygous or heterozygous.
  • Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene.
  • a system that may be produced is the cre/loxP recombinase system of bacteriophage PI (Lakso et al, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required.
  • Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
  • a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182).
  • both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) Nat Genet 25:83-6).
  • the genetically modified animals can be used in genetic studies to further elucidate the Apaf-1 pathway, as animal models of disease and disorders implicating defective Apaf-1 function, and for in vivo testing of candidate therapeutic agents, such as those identified in screens described below.
  • the candidate therapeutic agents are administered to a genetically modified animal having altered FLJl 115 function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered FLJl 115 expression that receive candidate therapeutic agent.
  • appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered FLJl 115 expression that receive candidate therapeutic agent.
  • FLJl 115 function animal models having defective Apaf-1 function (and otherwise normal FLJl 115 function), can be used in the methods of the present invention.
  • a Apaf-1 knockout mouse can be used to assess, in vivo, the activity of a candidate Apaf-1 modulating agent identified in one of the in vitro assays described below.
  • the candidate Apaf-1 modulating agent when administered to a model system with cells defective in Apaf-1 function, produces a detectable phenotypic change in the model system indicating that the Apaf-1 function is restored, i.e., the cells exhibit normal cell cycle progression.
  • the invention provides methods to identify agents that interact with and/or modulate the function of FLJl 115 and/or the Apaf-1 pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the Apaf-1 pathway, as well as in further analysis of the FLJl 115 protein and its contribution to the Apaf-1 pathway. Accordingly, the invention also provides methods for modulating the Apaf-1 pathway comprising the step of specifically modulating FLJl 115 activity by administering a FLJl 115 -interacting or -modulating agent.
  • an "FLJl 115-modulating agent" is any agent that modulates
  • FLJl 115 function for example, an agent that interacts with FLJl 115 to inhibit or enhance FLJl 115 activity or otherwise affect normal FLJl 115 function.
  • FLJl 115 function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity.
  • the FLJl 115 - modulating agent specifically modulates the function of the FLJl 115.
  • the phrases "specific modulating agent”, “specifically modulates”, etc., are used herein to refer to modulating agents that directly bind to the FLJl 115 polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the FLJl 115.
  • the FLJl 115-modulating agent is a modulator of the Apaf-1 pathway (e.g. it restores and/or upregulates Apaf-1 function) and thus is also a Apaf-1 -modulating agent.
  • Preferred FLJl 115-modulating agents include small molecule compounds; FLJl 115 -interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors.
  • the modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences” Mack Publishing Co., Easton, PA, 19 th edition. Small molecule modulators
  • Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains.
  • Chemical agents referred to in the art as "small molecule” compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500.
  • This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the FLJl 115 protein or may be identified by screening compound libraries.
  • modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for FLJl 115-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948). Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the Apaf-1 pathway.
  • candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing.
  • candidate clinical compounds are generated with specific regard to clinical and pharmacological properties.
  • the reagents may be derivatized and re-screened using in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development.
  • FLJl 115-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the Apaf-1 pathway and related disorders, as well as in validation assays for other FLJl 115-modulating agents.
  • FLJl 115-interacting proteins affect normal FLJl 115 function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity.
  • FLJl 115-interacting proteins are useful in detecting and providing information about the function of FLJl 115 proteins, as is relevant to Apaf-1 related disorders, such as cancer (e.g., for diagnostic means).
  • An FLJl 115-interacting protein may be endogenous, i.e.
  • FLJl 115- modulators include dominant negative forms of FLJl 115-interacting proteins and of FLJl 115 proteins themselves.
  • Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous FLJl 115-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp.
  • Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3 rd , Trends Genet (2000) 16:5-8).
  • An FLJl 115-interacting protein may be an exogenous protein, such as an FLJl 115-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). FLJl 115 antibodies are further discussed below.
  • an FLJl 115-interacting protein specifically binds an FLJl 115 protein.
  • an FLJl 115-modulating agent binds an FLJl 115 substrate, binding partner, or cofactor.
  • the protein modulator is an FLJl 115 specific antibody agonist or antagonist.
  • the antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify FLJl 115 modulators.
  • the antibodies can also be used in dissecting the portions of the FLJl 115 pathway responsible for various cellular responses and in the general processing and maturation of the FLJl 115.
  • Antibodies that specifically bind FLJl 115 polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of FLJl 115 polypeptide, and more preferably, to human FLJl 115. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, anti- idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • mAbs monoclonal
  • Fab fragments fragments
  • F(ab').sub.2 fragments fragments produced by a FAb expression library
  • anti-Id anti- idiotypic antibodies
  • Epitopes of FLJl 115 which are particularly antigenic can be selected, for example, by routine screening of FLJl 115 polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Nati. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence shown in SEQ ID NO:2.
  • Monoclonal antibodies with affinities of 10 8 M “1 preferably 10 9 M “1 to 10 10 M “1 , or stronger can be made by standard procedures as described (Harlow and Lane, supra; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577).
  • Antibodies may be generated against crude cell extracts of FLJl 115 or substantially purified fragments thereof. If FLJl 115 fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an FLJl 115 protein.
  • FLJl 115-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response.
  • the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response.
  • KLH keyhole limpet hemocyanin
  • An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.
  • FLJl 115-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding FLJl 115 polypeptides.
  • an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding FLJl 115 polypeptides.
  • ELISA enzyme-linked immunosorbant assay
  • Other assays such as radioimmunoassays or fluorescent assays might also be used.
  • Chimeric antibodies specific to FLJl 115 polypeptides can be made that contain different portions from different animal species.
  • a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment.
  • Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31 :452-454).
  • Humanized antibodies which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ⁇ 10% murine sequences and ⁇ 90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).
  • FLJl 115-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).
  • T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, supra).
  • polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134).
  • labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos.
  • the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously.
  • the therapeutically effective dose and dosage regimen is determined by clinical studies.
  • the amount of antibody administered is in the range of about 0.1 mg/kg -to about 10 mg/kg of patient weight.
  • the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle.
  • a pharmaceutically acceptable vehicle are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin.
  • Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used.
  • the vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential.
  • the antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to aboutlO mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).
  • an FLJl 115-interacting protein may have biotherapeutic applications.
  • Biotherapeutic agents formulated in pharmaceutically acceptable carriers and dosages may be used to activate or inhibit signal transduction pathways. This modulation may be accomplished by binding a ligand, thus inhibiting the activity of the pathway; or by binding a receptor, either to inhibit activation of, or to activate, the receptor.
  • the biotherapeutic may itself be a ligand capable of activating or inhibiting a receptor. Biotherapeutic agents and methods of producing them are described in detail in U.S. Pat. No. 6,146,628.
  • FLJl 115, its ligand(s), antibodies to the ligand(s) or the FLJl 115 itself may be used as biotherapeutics to modulate the activity of FLJl 115 in the Apaf-1 pathway.
  • FLJl 115-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit
  • FLJl 115 activity Preferred nucleic acid modulators interfere with the function of the FLJl 115 nucleic acid such as DNA replication, transcription, translocation of the FLJl 115 RNA to the site of protein translation, translation of protein from the FLJl 115 RNA, splicing of the FLJl 115 RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the FLJl 115 RNA.
  • the antisense oligomer is an oligonucleotide that is sufficiently complementary to an FLJl 115 mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region.
  • FLJl 115-specific antisense oligonucleotides preferably range from at least 6 to about 200 nucleotides.
  • the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length.
  • the oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded.
  • the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone.
  • the oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.
  • the antisense oligomer is a phosphothioate morpholino oligomer (PMO).
  • PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7: 187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).
  • RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene.
  • dsRNA double-stranded RNA
  • Methods relating to the use of RNAi to silence genes in C. elegans, Drosophila, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S.
  • Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with seventeen specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway.
  • an FLJl 115-specific nucleic acid modulator is used in an assay to further elucidate the role of the FLJl 115 in the Apaf-1 pathway, and/or its relationship to other members of the pathway.
  • an FLJl 115-specific antisense oligomer is used as a therapeutic agent for treatment of Apaf- 1 -related disease states.
  • an "assay system” encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event.
  • primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the FLJl 115 nucleic acid or protein.
  • secondary assays further assess the activity of a FLJl 115 modulating agent identified by a primary assay and may confirm that the modulating agent affects FLJl 115 in a manner relevant to the Apaf-1 pathway. In some cases, FLJl 115 modulators will be directly tested in a secondary assay.
  • the screening method comprises contacting a suitable assay system comprising an FLJl 115 polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. binding activity), which is based on the particular molecular event the screening method detects.
  • a reference activity e.g. binding activity
  • a statistically significant difference between the agent- biased activity and the reference activity indicates that the candidate agent modulates FLJl 115 activity, and hence the Apaf-1 pathway.
  • the FLJl 115 polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.
  • the type of modulator tested generally determines the type of primary assay.
  • screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS et al, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references).
  • the term "cell-based” refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction.
  • cell free encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts.
  • Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (e.g., receptor-ligand binding), transcriptional activity (e.g., using a reporter gene), enzymatic activity (e.g., via a property of the substrate), activity of second messengers, immunogenicty and changes in cellular morphology or other cellular characteristics.
  • Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.
  • Cell-based screening assays usually require systems for recombinant expression of FLJl 115 and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when FLJl 115-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the FLJl 115 protein may be assayed by various known methods such as substrate processing (e.g.
  • binding equilibrium constants usually at least about preferably at least about 10 8 M "1 , more preferably at least about 10 9 M "1
  • immunogenicity e.g. ability to elicit FLJl 115 specific antibody in a heterologous host such as a mouse, rat, goat or rabbit.
  • binding may be assayed by, respectively, substrate and ligand processing.
  • the screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a FLJl 115 polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein.
  • the FLJl 115 polypeptide can be full length or a fragment thereof that retains functional FLJl 115 activity.
  • the FLJl 115 polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag.
  • the FLJl 115 polypeptide is preferably human FLJl 115, or is an ortholog or derivative thereof as described above.
  • the screening assay detects candidate agent-based modulation of FLJl 115 interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has FLJl 115 -specific binding activity, and can be used to assess normal FLJl 115 gene function.
  • a binding target such as an endogenous or exogenous protein or other substrate that has FLJl 115 -specific binding activity
  • Suitable assay formats that may be adapted to screen for FLJl 115 modulators are known in the art.
  • Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr Opin Biotechnol 2000, 11:47-53).
  • screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (e.g., Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, supra; Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451).
  • fluorescence technologies including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer.
  • a variety of suitable assay systems may be used to identify candidate FLJl 115 and Apaf-1 pathway modulators (e.g. U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below.
  • Apoptosis assays may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay.
  • TUNEL terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling
  • the TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis ( Lazebnik et al, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara et al, 1989, J. Exp. Med. 169, 1747).
  • Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41).
  • An apoptosis assay system may comprise a cell that expresses an FLJl 115, and that optionally has defective Apaf-1 function (e.g. Apaf-1 is over-expressed or under- expressed relative to wild-type cells).
  • a test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate Apaf-1 modulating agents.
  • an apoptosis assay may be used as a secondary assay to test a candidate Apaf-1 modulating agents that is initially identified using a cell-free assay system.
  • An apoptosis assay may also be used to test whether FLJl 115 function plays a direct role in apoptosis.
  • an apoptosis assay may be performed on cells that over- or under-express FLJl 115 relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the FLJl 115 plays a direct role in the apoptotic response.
  • Apoptosis assays are described further in US Pat. No. 6,133,437.
  • Cell proliferation and cell cycle assays may be assayed via bromodeoxyuridine (BRDU) incorporation.
  • BRDU bromodeoxyuridine
  • This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino et al, 1986, Int. J. Cancer 38, 369; Campana et al, 1988, J. Immunol. Meth. 107, 79), or by other means.
  • Cell Proliferation may also be examined using [ 3 H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73).
  • This assay allows for quantitative characterization of S-phase DNA syntheses.
  • cells synthesizing DNA will incorporate [ 3 H]-thymidine into newly synthesized DNA.
  • Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter).
  • Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL et al., 1998, In Vitro Cell Dev Biol Anim 34:239-46).
  • Cell proliferation may also be assayed by colony formation in soft agar (Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with FLJl 115 are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.
  • Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55).
  • Cells transfected with an FLJl 115 may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.
  • a cell proliferation or cell cycle assay system may comprise a cell that expresses an FLJl 115, and that optionally has defective Apaf-1 function (e.g. Apaf-1 is over-expressed or under-expressed relative to wild-type cells).
  • a test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate Apaf-1 modulating agents.
  • the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate Apaf-1 modulating agents that is initially identified using another assay system such as a cell-free assay system.
  • a cell proliferation assay may also be used to test whether FLJl 115 function plays a direct role in cell proliferation or cell cycle.
  • a cell proliferation or cell cycle assay may be performed on cells that over- or under-express FLJl 115 relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the FLJl 115 plays a direct role in cell proliferation or cell cycle.
  • Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson).
  • Alamar Blue based assays available from Biosource International
  • migration assays using fluorescent molecules such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors
  • tubule formation assays based on the formation of tubular structures by endothelial cells on Ma
  • an angiogenesis assay system may comprise a cell that expresses an FLJl 115, and that optionally has defective Apaf-1 function (e.g. Apaf-1 is over-expressed or under-expressed relative to wild-type cells).
  • a test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate Apaf-1 modulating agents.
  • the angiogenesis assay may be used as a secondary assay to test a candidate Apaf-1 modulating agents that is initially identified using another assay system.
  • An angiogenesis assay may also be used to test whether FLJl 115 function plays a direct role in cell proliferation.
  • an angiogenesis assay may be performed on cells that over- or under-express FLJl 115 relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the FLJl 115 plays a direct role in angiogenesis.
  • hypoxia inducible factor- 1 The alpha subunit of the transcription factor, hypoxia inducible factor- 1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro.
  • HJF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glyolytic enzymes and VEGF.
  • Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with FLJl 115 in hypoxic conditions (such as with 0.1% 02, 5% C02, and balance N2, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®.
  • a hypoxic induction assay system may comprise a cell that expresses an FLJl 115, and that optionally has a mutated Apaf-1 (e.g. Apaf-1 is over-expressed or under-expressed relative to wild-type cells).
  • a test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate Apaf-1 modulating agents.
  • the hypoxic induction assay may be used as a secondary assay to test a candidate Apaf-1 modulating agents that is initially identified using another assay system.
  • a hypoxic induction assay may also be used to test whether FIJI 115 function plays a direct role in the hypoxic response.
  • a hypoxic induction assay may be performed on cells that over- or under-express FLJl 115 relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the FLJl 115 plays a direct role in hypoxic induction.
  • Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents.
  • Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2x final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.
  • a membrane-permeable fluorescent dye such as calcein-AM
  • Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice.
  • cells expressing the cell adhesion protein are plated in wells of a multiwell plate.
  • Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF , and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.
  • High-throughput cell adhesion assays have also been described.
  • small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off.
  • this assay not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).
  • ELISA enzyme-linked immunosorbant assay
  • screening assays described for small molecule modulators may also be used to test antibody modulators.
  • primary assays may test the ability of the nucleic acid modulator to inhibit or enhance FLJl 115 gene expression, preferably mRNA expression.
  • expression analysis comprises comparing FLJl 115 expression in like populations of cells (e.g., two pools of cells that endogenously or recombinantly express FLJl 115) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art.
  • Northern blotting For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (e.g., using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that FLJl 115 mRNA expression is reduced in cells treated with the nucleic acid modulator (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM et al, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM et al, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47).
  • the nucleic acid modulator e.g., Current Protocols in Molecular Biology (1994) Ausubel FM et al, eds., John Wiley & Sons, Inc.
  • Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the FLJl 115 protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, supra).
  • screening assays described for small molecule modulators may also be used to test nucleic acid modulators.
  • Secondary assays may be used to further assess the activity of FLJl 115- modulating agent identified by any of the above methods to confirm that the modulating agent affects FLJl 115 in a manner relevant to the Apaf-1 pathway.
  • FLJl 115-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with FLJl 115.
  • Secondary assays generally compare like populations of cells or animals (e.g., two pools of cells or animals that endogenously or recombinantly express FLJl 115) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate FLJl 115-modulating agent results in changes in the Apaf-1 pathway in comparison to untreated (or mock- or placebo- treated) cells or animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the Apaf-1 or interacting pathways. Cell-based assays
  • Cell based assays may detect endogenous Apaf-1 pathway activity or may rely on recombinant expression of Apaf-1 pathway components. Any of the aforementioned assays may be used in this cell-based format.
  • Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.
  • a variety of non-human animal models of normal or defective Apaf-1 pathway may be used to test candidate FLJl 115 modulators.
  • Models for defective Apaf-1 pathway typically use genetically modified animals that have been engineered to mis-express (e.g., over-express or lack expression in) genes involved in the Apaf-1 pathway.
  • Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.
  • Apaf-1 pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal Apaf-1 are used to test the candidate modulator's affect on FLJ1115 in Matrigel® assays.
  • Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen TV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over- express the FLJl 115. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (JP), or intravenous (IV) routes with the candidate modulator.
  • PO oral
  • JP intraperitoneal
  • IV intravenous
  • mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.
  • the effect of the candidate modulator on FLJl 115 is assessed via tumorigenicity assays.
  • Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or .from in vitro culture. The tumors which express the FLJl 115 endogenously are injected in the flank, 1 x 10 5 to 1 x 10 7 cells per mouse in a volume of 100 ⁇ L using a 27gauge needle.
  • mice are then ear tagged and tumors are measured twice weekly.
  • Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg.
  • Candidate modulator is delivered IV, SC, IP, or PO by bolus administration.
  • dosing can be performed multiple times per day.
  • the tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions.
  • the excised tumors maybe utilized for biomarker identification or further analyses.
  • xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.
  • tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413.
  • the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate modulator.
  • Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator.
  • Tumorogenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.
  • a tumorogenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays.
  • tumor development in the transgenic model is well characterized or is controlled.
  • the "RIPl-Tag2" transgene comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812).
  • the RIP1-TAG2 mice die by age 14 weeks.
  • Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression).
  • Tumorogenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.
  • the invention also provides methods for modulating the Apaf-1 pathway in a cell, preferably a cell pre-determined to have defective or impaired Apaf-1 function (e.g. due to overexpression, underexpression, or misexpression of Apaf-1, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates FLJl 115 activity.
  • the modulating agent produces a detectable phenotypic change in the cell indicating that the Apaf-1 function is restored.
  • the phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored Apaf-1 function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells.
  • the invention also provides methods for treating disorders or disease associated with impaired Apaf-1 function by administering a therapeutically effective amount of an FLJl 115 -modulating agent that modulates the Apaf-1 pathway.
  • the invention further provides methods for modulating FLJl 115 function in a cell, preferably a cell pre-determined to have defective or impaired FLJl 115 function, by administering an FLJl 115 -modulating agent.
  • the invention provides a method for treating disorders or disease associated with impaired FLJl 115 function by administering a therapeutically effective amount of an FLJl 115 -modulating agent.
  • FLJl 115 is implicated in Apaf-1 pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the Apaf-1 pathway and for the identification of subjects having a predisposition to such diseases and disorders.
  • Various expression analysis methods can be used to diagnose whether FLJl 115 expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis, (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM et al, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM et al, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47).
  • Tissues having a disease or disorder implicating defective Apaf-1 signaling that express an FLJl 115 are identified as amenable to treatment with an FLJl 115 modulating agent.
  • the Apaf-1 defective tissue overexpresses an FLJl 115 relative to normal tissue.
  • a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial FLJl 115 cDNA sequences as probes can determine whether particular tumors express or overexpress FLJl 115.
  • the TaqMan® is used for quantitative RT-PCR analysis of FLJl 115 expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).
  • reagents such as the FLJl 115 oligonucleotides, and antibodies directed against an FLJl 115, as described above for: (1) the detection of the presence of FLJl 115 gene mutations, or the detection of either over- or under-expression of FLJl 115 mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of FLJl 115 gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by FLJl 115.
  • the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in FLJl 115 expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for FLJl 115 expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder.
  • the disease is cancer, most preferably colon cancer.
  • the probe may be either DNA or protein, including an antibody.
  • proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies.
  • the reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).
  • NCI National Cancer Institute
  • ATCC American Type Culture Collection, Manassas, VA 20110-2209
  • Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, Stratagene, Ardais, Genome Collaborative, and Ambion.
  • Taqman reactions were carried out following manufacturer's protocols, in 25 ⁇ l total volume for 96-well plates and 10 ⁇ l total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA.
  • the standard curve for result analysis was prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good.
  • the raw data were normalized using 18S rRNA (universally expressed in all tissues and cells).
  • tumor tissue samples were compared with matched normal tissues from the same patient.
  • a gene was considered overexpressed in a tumor when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample.
  • a universal pool of cDNA samples was used instead.
  • a gene was considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., Tumor - average(all normal samples) > 2 x STDEV(all normal samples) ).
  • FLJl 115 (SEQ ID NO: 1) was overexpressed in 2 of 12 breast tumors, 8 of 30 colon tumors, 1 of 14 lung tumors, and 1 of 7 ovarian tumors.
  • a modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator.
  • the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator.
  • the expression data for the gene(s) can also be used as a diagnostic marker for disease progression.
  • the assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Selon cette invention, on identifie des gènes humains FLJ1115 comme modulateurs du mécanisme d'action d'Apaf-1, ces gènes étant, par conséquent, des cibles thérapeutiques pour des troubles associés à la fonction défectueuse d'Apaf-1. L'invention porte sur des procédés d'identification des modulateurs de l'Apaf-1, ces procédés consistant à cribler des agents qui modulent l'activité de FLJ1115.
PCT/US2002/039867 2001-12-13 2002-12-12 Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation WO2003052069A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002360586A AU2002360586A1 (en) 2001-12-13 2002-12-12 FLJ1115 AS MODIFIER OF THE Apaf-1 PATHWAY AND METHODS OF USE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34031301P 2001-12-13 2001-12-13
US60/340,313 2001-12-13
US35744702P 2002-02-15 2002-02-15
US60/357,447 2002-02-15

Publications (2)

Publication Number Publication Date
WO2003052069A2 true WO2003052069A2 (fr) 2003-06-26
WO2003052069A3 WO2003052069A3 (fr) 2004-01-29

Family

ID=26992055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039867 WO2003052069A2 (fr) 2001-12-13 2002-12-12 Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU2002360586A1 (fr)
WO (1) WO2003052069A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065937A2 (fr) * 1998-06-16 1999-12-23 Thomas Jefferson University Apaf-1 tronquee et ses procedes d'utilisation
US6228603B1 (en) * 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
US6291643B1 (en) * 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228603B1 (en) * 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
US6291643B1 (en) * 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
WO1999065937A2 (fr) * 1998-06-16 1999-12-23 Thomas Jefferson University Apaf-1 tronquee et ses procedes d'utilisation

Also Published As

Publication number Publication date
WO2003052069A3 (fr) 2004-01-29
AU2002360586A8 (en) 2003-06-30
AU2002360586A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
WO2003074674A2 (fr) Genes msra utilises en tant que modificateurs de la voie p53 et procedes d'utilisation associes
WO2002099055A2 (fr) Cip comme modificateurs de la voie p53 et methodes d'utilisation associees
US20030027230A1 (en) HPRP4s as modifiers of the p53 pathway and methods of use
US20060084063A1 (en) Rabs as modifiers of the p53 pathway and methods of use
WO2004024884A2 (fr) Syt utilises en tant que modificateurs de la voie p21 et procedes d'utilisation
WO2004048537A2 (fr) « lamps » modifiant la voie p53 et leurs procedes d'utilisation
WO2003035831A2 (fr) Lrrcaps en tant que modificateurs de la voie de passage p53 et leurs procedes d'utilisation
US20110167505A1 (en) GFATS As Modifiers of the AXIN Pathway and Methods of Use
WO2004005483A2 (fr) Adcy3s modificateurs de la voie p21 et methodes d'utilisation
WO2003074725A2 (fr) Mbcat comme modificateurs du mecanisme d'action de la $g(b)-catenine et procedes d'utilisation correspondants
WO2003035832A2 (fr) Ctsls en tant que modificateurs des voies de passage de p53 et de apaf-1 et leurs procedes d'utilisation
WO2003052069A2 (fr) Flj1115 utile comme modificateur du mecanisme d'action d'apaf-1 et procedes d'utilisation
WO2004048536A2 (fr) Rhebs utilises comme modificateurs de la voie rb et methodes d'utilisation
EP1578948A2 (fr) Flj10607 utilise en tant que modificateur de la voie de l'axine et procedes d'utilisation correspondants
WO2003052070A2 (fr) Genes vps41 en tant que modificateurs de la mort cellulaire et procedes d'utilisation associe
WO2003052066A2 (fr) Klcs utilises en tant que genes modificateurs de la voie p53 et procedes d'utilisation correspondant
WO2003074672A2 (fr) Crebpa tenant lieu de modificateurs de voies de mort cellulaire et leurs procedes d'utilisation
AU2002337914A1 (en) LRRCAPS as modifiers of the p53 pathway and methods of use
EP1633852A2 (fr) Sppls utilises en tant que modificateurs de la voie p53 et procedes d'utilisation
WO2003074671A2 (fr) Mbcat tenant lieu de modificateurs de la voie d'une beta-catenine et leurs procedes d'utilisation
AU2002324599A1 (en) hPRP4s as modifiers of the p53 pathway and methods of use
WO2003074663A2 (fr) Genes mp21 utilises comme modificateurs de la voie p21 et procedes d'utilisation correspondants
WO2004024881A2 (fr) Ldlr utilise en tant que modificateur de la voie p53 et procedes d'utilisation associes
AU2002310273A1 (en) SLC2As as modifiers of the P53 pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP